ClinicalTrials.gg
CompletedNCT06671444Updated Jun 30, 2026

Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impairment

A Phase 1 interventional study of YZJ-1139 in Insomnia and Renal Impairment, sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd.. Completed at 3 sites in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2024, registered Oct 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China — 82 open to participants now, 88 under way, 2 of them phase 3. Sleep Initiation and Maintenance Disorders · China.

Enrollment
156th of 162
16 · median 88
Started
2024
with 44 others
Phase 1
13 of 198
1 open now
Registered
125th of 198
by date
Lead sponsor
9 of 198
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Among the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, this one is the 156th largest by enrollment of the 162 interventional ones that give a count, is one of 45 that started in 2024, is one of 13 in phase 1, and was the 125th registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

82 of the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, or all of them as a file.
02

Study summary

Objective:

  1. To evaluate the pharmacokinetics of YZJ-1139 tablets in patients with severe renal impairment and in subjects with normal renal impairment.
  2. To evaluate the safety of YZJ-1139 tablets in patients with severe renal impairment and in subjects with normal renal impairment.
03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Entry criteria(Group A-Severe Renal Impairment Group):

  1. Male or female subjects aged 18-65 years (inclusive).
  2. Weight ≥ 50.0 kg for males, or ≥ 45.0 kg for females, and (BMI) in the range of 19.0 \~ 28.0 kg/m2 (inclusive).
  3. Subjects has been diagnosed with chronic kidney disease (more than 3 months) and have stable renal function (absolute change within 25% at least 1 month at screening), absolute eGFR at screening meets the renal function classification criteria, severe renal insufficiency: 15 \~ 29 mL/min;.
  4. Subjects of (including partners) have no family planning or donate sperm/eggs from 2 weeks before screening to 3 months after dosing, and voluntarily take appropriate measures;
  5. Subjects who are able to understand and willing to complete the study in strict compliance with the clinical protocol and sign the form

Exclusion criteria(Group A-Severe Renal Impairment Group):

  1. Allergic constitution, such as those with a known history of allergies to drugs, food or other substances, or those with a history of allergies to YZJ-1139 tablets or similar orexin receptor antagonist drugs and ;
  2. Subjects with difficulty swallowing tablets, and special dietary requirements who cannot accept a unified diet;
  3. Subjects who have poor peripheral venous access or cannot tolerate venous puncture or have a history of needle and blood fainting;
  4. Subjects who have undergone surgery within 30 days prior to screening, or plan to undergo surgery during the study;
  5. Individuals with a history of paroxysmal sleep disorder, obstructive sleep apnea, complex sleep behavior (such as dream walking, driving in dreams, etc.), severe unconscious hypoglycemia, stroke, epilepsy, and other psychiatric disorders (including anxiety, depression, etc.), convulsive diseases, and sudden onset of illness;
  6. Patients who have received kidney transplantation and/or require renal dialysis during the trial.
  7. Except for the disease causing renal dysfunction itself, those who have previously or currently suffered from other serious systemic organ diseases, including respiratory, digestive, endocrine, malignant tumor, blood, mental/nervous system serious diseases, which were judged by the investigator to be unsuitable for participation in this trial;
  8. Subjects with and/or AST > 2 and/or > 1.5 ULN, \< 80 g/L, > 450 ms in males and QTcF > 470 ms in females by .
  9. Subjects with poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg) or heart rate > 120bmp.
  10. Patients with diabetic nephropathy HbAlc (glycosylated hemoglobin) > 8.5% or fasting blood glucose > 8.5 mmol/L, or stable treatment regimen for less than 1 month before screening.
  11. Subjects with active infection (HBV DNA copy number ≥ 104 copies/mL must be excluded if HBsAg is positive), or those who are positive in any index screening of , antibody, syphilis antibody.
  12. Subjects with a history of drug abuse, drug use within 6 months before screening, or positive drug abuse screening;
  13. Subjects who frequently consume alcohol within 3 months prior to screening, i.e., consuming more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% spirits, or 150 mL of wine), or who cannot stop using any alcohol products during the study, or alcohol breath test result > 0.0 mg/100 mL;
  14. Subjects who have donated blood or experienced massive blood loss (> 400 mL) within 3 months prior to screening, received blood transfusions or used blood products, planned to donate blood during the trial period or within 1 month after the end of the trial;
  15. Subjects who have consumed excessive tea, coffee and/or caffeine-containing beverages (more than 8 cups, 1 cup ≈ 250 mL) daily during the 3 months before screening;
  16. Subjects smoke an average of 5 or more cigarettes per day within 3 months prior to screening, or those who cannot stop using any tobacco products during the study;
  17. Subjects who have participated in any clinical trial and have used clinical trial drugs within 3 months prior to screening, or plan to participate in other clinical trials during the study;
  18. Subjects who have received vaccination within 30 days prior to screening, or plan to receive vaccination during the study;
  19. Subjects who have used any enzyme inducer or inhibitor within 30 days (or 5 half-lives, whichever is longer) prior to administration;
  20. Subjects who have used any prescription drugs, over-the-counter drugs, vitamin products, health products or Chinese herbal medicines other than those for the treatment of renal insufficiency and or its concomitant chronic diseases within 14 days before administration;
  21. Subjects who started taking new drugs, dosage forms or adjusted current doses for the treatment of chronic kidney disease and its combined chronic diseases within 14 days before administration;
  22. Subjects who have consumed special diets (including grapefruit, chocolate, xanthine-rich or alcohol-rich foods/beverages) within 48 h before administration;
  23. Lactating women, or women who test positive for pregnancy;
  24. Subjects with acute illness from screening to prior to administration;
  25. Those who, in the opinion of the investigator, are not suitable for inclusion.

Entry criteria(Group B-Healthy Subject Group):

  1. Subjects aged 18 to 65 years (inclusive), matched with renal impairment for age and sex (each subject in Group B within± 10 years of the mean for Group A and with a mean of ± 1 case for Group A by gender);
  2. Weight ≥ 50.0 kg for males, or ≥ 45.0 kg for females, and body mass index (BMI) in the range of 19.0 \~ 28.0 kg/m2 (inclusive), matched to BMI with renal impairment group (each subject in Group B within ±15% of mean in Group A by BMI).
  3. Normal renal function, 90 mL/min ≤ absolute eGFR \< 130 mL/min;
  4. Subjects with normal physical examination, vital signs (normal range refers to central SOP), 12-lead ECG, laboratory tests, imaging and abdominal ultrasonography results during the screening period or abnormal but no clinical significance as judged by the investigator;
  5. Subjects of childbearing potential (including partners) have no family planning or donate sperm/eggs from 2 weeks before screening to 3 months after dosing, and voluntarily take appropriate contraceptive measures;
  6. Subjects who are able to understand and willing to complete the study in strict compliance with the clinical protocol and sign the informed consent form.

Exclusion criteria(Group B-Healthy Subject Group):

  1. Allergic constitution, such as those with a known history of allergies to drugs, food or other substances, or those with a history of allergies to YZJ-1139 tablets or similar orexin receptor antagonist drugs and excipients;
  2. Subjects with difficulty swallowing tablets, and special dietary requirements who cannot accept a unified diet;
  3. Subjects who have poor peripheral venous access or cannot tolerate venous puncture or have a history of needle and blood fainting;
  4. Individuals with a history of paroxysmal sleep disorder, obstructive sleep apnea, complex sleep behavior (such as dream walking, driving in dreams, etc.), severe unconscious hypoglycemia, stroke, epilepsy, and other psychiatric disorders (including anxiety, depression, etc.), convulsive diseases, and sudden onset of illness;
  5. Subjects who have a history of other serious diseases and chronic diseases such as respiratory system, circulatory system, digestive system, urinary system, blood system, endocrine system, immune system, nervous system, mental system;
  6. Those who are positive in any index screening of hepatitis B virus surface antigen, Treponema pallidum-specific antibody, human immunodeficiency virus antibody,or hepatitis C virus antibody;
  7. 12) Subjects with a history of drug abuse, drug use within 6 months before screening, or positive drug abuse screening;
  8. Subjects who frequently consume alcohol within 3 months prior to screening, i.e., consuming more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% spirits, alcohol or 150 mL of wine), or who cannot stop using any alcohol products during the study, or whose alcohol breath test result > 0.0 mg/100 mL;
  9. Subjects who have donated blood or experienced massive blood loss (> 400 mL) within 3 months prior to screening, received blood transfusions or used blood products, planned to donate blood during the trial period or within 1 month after the end of the trial;
  10. Subjects who have consumed excessive tea, coffee and/or caffeine-containing beverages (more than 8 cups, 1 cup ≈ 250 mL) daily during the 3 months before screening;
  11. Subjects smoke an average of 5 or more cigarettes per day within 3 months prior to screening, or those who cannot stop using any tobacco products during the study;
  12. Subjects who have participated in any clinical trial and have used clinical trial drugs within 3 months prior to screening, or plan to participate in other clinical trials during the study;
  13. Subjects who have undergone surgery within 30 days prior to screening, or plan to undergo surgery during the study;
  14. Subjects who have received vaccination within 30 days prior to screening, or plan to receive vaccination during the study;
  15. Subjects who have used any CYP3A4 enzyme inducer or inhibitor within 30 days (or 5 half-lives, whichever is longer) prior to administration;
  16. Subjects who have taken any prescription drugs, over-the-counter drugs, health products, vitamins, and Chinese herbal medicines within 14 days before administration;
  17. Subjects who have consumed special diets (including grapefruit, chocolate, xanthine-rich or alcohol-rich foods/beverages) within 48 h before administration;
  18. Lactating women, or women who test positive for pregnancy;
  19. Subjects with acute illness from screening period to pre-dose;
  20. Those who, in the opinion of the investigator, are not suitable for inclusion.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Group A: Severe Renal Impairment

    Drug: YZJ-1139

  • Experimental
    Group B: Normal Renal Impairment

    Drug: YZJ-1139

Interventions

  • Single oral dose, 20 mg tablet

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC0-t) of YZJ-1139

    AUClast is defined as the concentration of drug from time zero to the last observable concentration

    Time frame: From Day 1 to Day 3

  2. Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC0-∞) of YZJ-1139

    AUCinf is defined as the concentration of drug extrapolated to infinite time

    Time frame: From Day 1 to Day 3

  3. Maximum Observed Plasma Concentration (Cmax) of YZJ-1139

    Cmax is defined as the maximum concentration of drug

    Time frame: From Day 1 to Day 3

  4. Apparent Oral Clearance (CL/F) of Entrectinib

    CL/F is defined as the apparent oral clearance following administration of the drug

    Time frame: From Day 1 to Day 3

  5. The Apparent Volume of Distribution (Vz/F) of Entrectinib

    Vz/F is defined as the apparent volume of distribution of the drug

    Time frame: From Day 1 to Day 3

  6. Time of Maximum Observed Plasma Concentration (Tmax) of Entrectinib

    Tmax is defined as the time (observed time point) of Cmax

    Time frame: From Day 1 to Day 3

  7. Apparent Terminal Elimination Half-life (t1/2) of Entrectinib

    Time frame: From Day 1 to Day 3

  8. Mean Residence Time (MRT0-t) of YZJ-1139

    Time frame: From Day 1 to Day 3

  9. Renal Excretion (Ae) of YZJ-1139

    Time frame: From Day 1 to Day 3

  10. renal clearance (CLR) of YZJ-1139

    Time frame: From Day 1 to Day 3

  11. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 to Day 7

07

Study locations

3 sites
  • Zhongda Hospital Southeast University
    Nanjing, Jiangsu, China
  • The First Affiliated Hospital of Bengbu Medical University
    Bengbu, China
  • The First Affiliated Hospital of Xuzhou Medical University
    Xuzhou, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Oct 2024, 4 months.

Of 23 industry-sponsored phase 1 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 4 months of starting (the median); a quarter within 1 and three quarters within 5. This study's 4 months is close to that.

Counting every sponsor, half of 39 studies reached it within 5 months; a quarter within 3 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2024
First posted
Nov 4, 2024
StartActual
Jun 3, 2024
Primary completionActual
Oct 11, 2024
CompletionActual
Nov 6, 2024
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06671444
Lead sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Nov 4, 2024
Start date
Jun 3, 2024
Primary completion
Oct 11, 2024
Completion
Nov 6, 2024
Last update
Jun 30, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fazamorexant

Start the discussion